Idiopathic pulmonary fibrosis

• Investigation of breathable surfactant agent in patients with idiopathic lung fibrosis Pending
  2023-508544-22-00 4
• A study to find an efficacious and safe dose of CHF10067 (zampilimab) in participants with idiopathic pulmonary fibrosis Pending
  2024-514246-37-00 4 "Idiopathic pulmonary fibrosis (IPF)"
• Study of Intravenous ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibros … Pending
  2024-518013-25-00 4 "Idiopathic Pulmonary Fibrosis"
• A Study to Evaluate the Long-term Safety and Tolerability of Admilparant in Participants with Pulmonary Fibrosis. Pending
  2025-522373-10-00 5 "Progressive pulmonary fibrosis and Idiopathic pulmonary fibr"
• A Phase 1, open label, randomised, 2-period, 2 sequence, 7-days repeat-dosing, crossover oral pharmacokinetic trial comparing multiple dosin … Pending
  2025-524883-39-00 3 "Cardiopulmonary diseases with contributions of thrombosis, r"
• AURA-IPF: A Randomized Phase 2 Study to evaluate the safety and efficacy of AP02 (nintedanib solution) in IPF Recruiting
  2025-523431-19-00 4 2026-05-20 "Idiopathic Pulmonary Fibrosis (IPF)"
• RENEW - A Phase 2 Study of the Safety, Tolerability and Efficacy of LTI-03 in Patients with Idiopathic Pulmonary Fibrosis Recruiting
  2025-520715-13-00 4 2026-04-22 "Idiopathic Pulmonary Fibrosis"
• Glucocorticoids versus placebo for the treatment of acute exacerbation of idiopathic pulmonary fibrosis: a randomized controlled trial Recruiting
  2024-514799-42-00 4 2024-11-05 "IDIOPATHIC PULMONARY FIBROSIS"
• A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis Recruiting
  2023-503697-21-01 5 2024-06-24
• A randomised, open-label, single-centre, drug-drug-interaction trial to evaluate the impact of carboxylesterase 2 (CES2)- and CYP3A4-inhibit … Recruiting
  2026-526135-18-00 3 2026-05-12
• Evaluation of MTX-463 in Participants with Idiopathic Pulmonary Fibrosis (IPF) Recruiting
  2025-521278-32-00 4 2025-12-04 "Idiopathic Pulmonary Fibrosis (IPF)"
• A follow-up study to test long-term treatment with BI 1015550 in people with pulmonary fibrosis who took part in a previous study with BI 10 … Recruiting
  2023-507353-15-00 5 2024-09-10 "idiopathic pulmonary fibrosis (IPF)"
• A Phase 2 Study of CAL101 in Patients with Idiopathic Pulmonary Fibrosis Recruitment ended
  2024-518339-12-00 4 2025-07-08 "Idiopathic Pulmonary Fibrosis"
• A Phase 2, Multi-Center, Randomized, Double-Blind, Controlled Trial Evaluating the Safety and Efficacy of ENV-101 in Patients with Lung Fibr … Recruitment ended
  2024-511754-41-00 4 2025-05-29 "idiopathic pulmonary fibrosis"
• A trial to evaluate efficacy and safety of buloxibutid in people with idiopathic pulmonary fibrosis Recruitment ended
  2023-509069-19-00 4 2024-12-12 "idiopathic pulmonary fibrosis"
• A 26-Week, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Efficacy, Safety, and Tolerability of Axatilimab … Recruitment ended
  2022-502954-15-00 4 2024-06-21
• A Randomized Double-blind Trial to Evaluate the Efficacy, Tolerability, Safety and Dose Response of LYT-100 in Patients with Idiopathic Pulm … Recruitment ended
  2024-511330-13-00 4 2023-01-17 "Idiopathic Pulmonary Fibrosis"
• Tezepelumab (Anti-TSLP-mab) in progressive pulmonary fibrosis interstitial lung disease with evidence of eosinophilia - A prospective two-ar … Halted
  2024-510884-51-00 4 2025-06-09 "Progressive pulmonary fibrosis interstitial lung disease wit"
• A randomised, open-label, 5-period, cross-over trial to assess the pharmacokinetics and safety of 3 oral solid formulations of buloxibutid ( … Ended
  2025-520702-35-00 3 2025-05-14 "Idiopahtic pulmonary fibrosis"
• Evaluation of safety, side effects and how the inhaled drug CHF10073 is absorbed, modified and removed from the body when administered alone … Ended
  2024-515442-17-00 1 2024-12-03 "Pulmonary fibrosis"
• A Phase 1/2a Study Evaluating the Effects of ARO-MMP7 Inhalation Solution in Healthy Subjects and Patients with Idiopathic Pulmonary Fibrosi … Ended
  2023-504964-41-00 7 2024-11-06
• A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Single and Multiple Do … Ended
  2023-504426-19-00 1 2024-10-01 "Pulmonary fibrosis"
• Study to assess the safety and tolerability of CMR316 in healthy volunteers and patients with Idiopathic Pulmonary Fibrosis. Ended
  2023-510456-23-00 1 2024-08-14 "Idiopathic Pulmonary Fibrosis"
• A randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of PLN-74809 (bexotegrast) for the tr … Ended
  2023-506185-31-00 10 2024-07-18 "Idiopathic pulmonary fibrosis (IPF)"

Showing 1–24 of 33 trials